Outlook Therapeutics CEO Russell Trenary resigns effective Dec 3; CFO Kenyon named interim CEO

Outlook Therapeutics, Inc.

C. Russell Trenary III stepped down as President, CEO and Board member on Dec 3, 2024, effective immediately.
Departure is a termination without cause; Trenary will receive severance benefits per his employment agreement.
Board reduced from ten to nine directors upon Trenary's resignation.
CFO Lawrence A. Kenyon, 59, appointed Interim CEO effective Dec 3 while Board searches for permanent CEO.
Kenyon continues as CFO during the interim period; no material arrangements or family relationships disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.